公开(公告)号：US20220289732A1

公开(公告)日：2022-09-15

申请号：US17633495

申请日：2020-08-07

Applicant: NOVARTIS AG

Inventor： Lichao FANG ,  Zhenting GAO ,  Xiangqing JIANG ,  Kevin Kun Chin LIU ,  Sing Yeung Frankie MAK ,  Counde OYANG ,  Ce WANG ,  Tao WANG ,  Jianping WU ,  Wu YINGMING ,  Qitao XIAO

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07D491/107 ,  C07D401/06 ,  C07D498/04 ,  C07D471/04 ,  C07D401/04

Abstract: The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.

公开(公告)号：US20220380371A1

公开(公告)日：2022-12-01

申请号：US17761902

申请日：2020-09-18

Applicant: NOVARTIS AG

Inventor： Ming LI ,  Kevin Kun Chin LIU ,  Chunliang LU ,  Zhuming SUN ,  Jichen ZHAO ,  Yihui ZHU

IPC: C07D473/34 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL).

公开(公告)号：US20220280509A1

公开(公告)日：2022-09-08

申请号：US17632990

申请日：2020-09-24

Applicant: Novartis AG

Inventor： Ling LI ,  Xuan DAI ,  Michael DORE ,  Xiang-Ju Justin GU ,  Kevin Kun Chin LIU ,  Sing Yeung Frankie MAK ,  Yuan MI ,  Counde OYANG ,  Julien PAPILLON ,  Wei (Vicky) QI ,  Xiaoxia YAN ,  Zhengtian YU ,  Ji Yue (Jeff) ZHANG ,  Kehao ZHAO

IPC: A61K31/506 ,  A61K45/06 ,  C07D471/04 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/541

Abstract: Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediate by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.